Zobrazeno 1 - 10 of 192 pro vyhledávání: '"G, Frasci"'
1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
4
Carboplatin and α-2b interferon intraperitoneal combination as first-line treatment of minimal residual ovarian cancer. A pilot study
Autor: S. Conforti, P. Mastrantonio, Rosario Vincenzo Iaffaioli, A. Cardone, G. Frasci, G. Persico, A. Tortoriello, G. Facchini
Publikováno v: European Journal of Cancer. 30:946-950
21 untreated ovarian cancer patients with stage III and minimal tumour size, were given weekly intraperitoneal (i.p.) carboplatin (150 mg/m2) and alpha-2b interferon (IFN) (30 million U/m2) for a total of 12 courses, from June 1989 to February 1993.
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ea270364c9589dabfa1cd7a2fd718ba
https://doi.org/10.1016/0959-8049(94)90120-1
Zobrazit plný text záznamu
5
Intraperitoneal (ip) Cisplatin-Mitoxantrone-Interferon-α2b in Ovarian Cancer Patients with Minimal Residual Disease
Autor: R.V. Iaffioli, P. Mastrantonio, A. Tortoriello, S. Conforti, Gaetano Facchini, A. Cardone, G. Persico, G. Frasci
Publikováno v: Gynecologic Oncology. 50:60-67
Forty-one ovarian cancer patients with less than 2 cm residual disease after systemic cisplatin-based chemotherapy received 4 courses of an ip regimen including cisplatin (75 mg/m2), mitoxantrone (20 mg/m2), and interferon-alpha 2b (30 mil IU/m2). Th
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::091c0e4d7200c7912577d53ed731c052
https://doi.org/10.1006/gyno.1993.1165
Zobrazit plný text záznamu
6
Impact of Preoperative CA 15-3 Levels in Operable Breast Cancer. Comparison with Tissue Polypeptide Antigen (TPA) and Carcinoembryonic Antigen (CEA)
Autor: C. Pagliarulo, G. Frasci, B. Ungaro, L. Bazzicalupo, Francesco Caponigro, Rosario Vincenzo Iaffaioli, S Deplacido, Ar Bianco, G. Esposito
Publikováno v: Scopus-Elsevier
CA 15-3, TPA and CEA were assayed before surgery in 60 patients with breast cancer. A significant association was found between preoperative CA 15-3 levels and some of the most important prognostic factors in breast cancer, such as lymph node status
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65c3a7e3729606b10394e4ed46d616d2
https://doi.org/10.1177/172460089100600104
Zobrazit plný text záznamu
9
Chlorambucil, Vincristine and Cytarabine (COA) treatment of low grade lymphomas
Autor: Ar Bianco, Vincenzo Montesarchio, C. Pagliarulo, Pierosandro Tagliaferri, R. Laurlv, A. Tortoriello, Rosario Vincenzo Iaffaioli, Gaetano Facchini, Elide Matano, Giovannella Palmieri, G. Frasci
Forty-five patients with stage III-IV low grade non-Hodgkin's lymphoma (NHL) were treated with a non-intensive polychemotherapy regimen including chlorambucil-vincristine and cytarabine (Ara-C), termed COA, for a total of 366 courses, beginning in Ju
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a8c8f3e8c87903c9f772e32686efd3d
http://hdl.handle.net/11588/337662
Zobrazit plný text záznamu
10
Additional Safety Results of Hannah: A Phase III Randomised, Open-Label, International Study of the Subcutaneous Formulation of Trastuzumab (H) in HER2-Positive Early Breast Cancer Patients
Autor: Magdolna Dank, M. Johnston, Dominik Heinzmann, Christian Jackisch, K. H. Park, R.I. Lopez, Harald A. Weber, G. Frasci, Gustavo Ismael
Publikováno v: Annals of Oncology. 23:ix102-ix103
Background HannaH demonstrated non-inferiority of the fixed-dose subcutaneous (SC) formulation of H compared with the intravenous (IV) formulation, based on co-primary endpoints of pharmacokinetics (Ctrough) and efficacy (pCR) (Jackisch et al, EBCC 2
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e4ca9263928627dbbc0fbeb5c214839e
https://doi.org/10.1016/s0923-7534(20)32833-7
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje